MUCERA Syrup 15mg5ml

Ülke: Malezya

Dil: İngilizce

Kaynak: NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

Aktif bileşen:

Ambroxol HCl

Mevcut itibaren:

THE ZYFAS MEDICAL CO.,

INN (International Adı):

Ambroxol HCl

Paketteki üniteler:

60ml mL

Tarafından üretildi:

PT OTTO PHARMACEUTICAL INDUSTRIES

Ürün özellikleri

MUCERA SYRUP 15MG/5ML
AMBROXOL HCI
COMPOSITION
Each 5 mL syrup contains:
Ambroxol HCI 15 mg
Preservatives:
Sodium benzoate 12.5mg
PRODUCT DESCRIPTION
Red solution , sweet and slightly bitter taste with strawberry odour
PHARMACODYNAMICS
The major pharmacodynamic actions of ambroxol are surfactant
stimulation, mucokinetic and
secretagogue activity. The therapeutic activities of the drug in
animal models of the infant and adult
respiratory distress syndrome (IRDS and ARDS) are reviewed. SO2
exposed rats, which exhibited
increased airway resistance and work of breathing, were used as an
animal model of a bronchitic
syndrome. The active group was treated with 25 mg kg-1 oral ambroxol
for 10 days. The airway
resistance of this group (53.6 +/- 7.0 Pa.ml-1.s) was significantly
lower than that of the control (81.2 +/-
11.4). Specific work of breathing was also lower in the treated group
(0.26 +/- 0.02 mJ.ml-1, control: 0.35
+/- 0.029). The alleviation of airflow limitation was a consequence of
subacute treatment and not of acute
bronchodilatation. Treatment with the beta 2-adrenergic drug
clenbuterol further improved both active and
placebo groups.
(Dr. Karl Thomae GmbH, Department of Biological Research, Biberach an
der Riss, Fed. Rep. Germany;
The pharmacology of ambroxol--review and new results. Eur J Respir Dis
Suppl. 1987;153:255-62.)
The mucokinetic activity of ambroxol was demonstrated as an increase
in mucus or particle transport rate
on the frog palate and in guinea pig tracheas. To clarify the
mechanism we examined the influence of the
drug on the ciliary beat frequency (CBF) of isolated cells from guinea
pig tracheas. Ambroxol significantly
stimulated the CBF up to 10.8%, salbutamol up to 19.5%. The effect of
ambroxol on CBF certainly
contributes to, but does not explain the more pronounced increase in
transport rate. Thus a stimulation of
the mucociliary transport rate by the other major pharmacodynamic
mechanisms, secretagogue activity
and stimulation of pulmonary surfactant, has to be considered. The
therape